Literature DB >> 20647428

Induction of broadly neutralizing H1N1 influenza antibodies by vaccination.

Chih-Jen Wei1, Jeffrey C Boyington, Patrick M McTamney, Wing-Pui Kong, Melissa B Pearce, Ling Xu, Hanne Andersen, Srinivas Rao, Terrence M Tumpey, Zhi-Yong Yang, Gary J Nabel.   

Abstract

The rapid dissemination of the 2009 pandemic influenza virus underscores the need for universal influenza vaccines that elicit protective immunity to diverse viral strains. Here, we show that vaccination with plasmid DNA encoding H1N1 influenza hemagglutinin (HA) and boosting with seasonal vaccine or replication-defective adenovirus 5 vector encoding HA stimulated the production of broadly neutralizing influenza antibodies. This prime/boost combination increased the neutralization of diverse H1N1 strains dating from 1934 to 2007 as compared to either component alone and conferred protection against divergent H1N1 viruses in mice and ferrets. These antibodies were directed to the conserved stem region of HA and were also elicited in nonhuman primates. Cross-neutralization of H1N1 subtypes elicited by this approach provides a basis for the development of a universal influenza vaccine for humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647428     DOI: 10.1126/science.1192517

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  202 in total

1.  DNA vaccination in the skin using microneedles improves protection against influenza.

Authors:  Jae-Min Song; Yeu-Chun Kim; Eunju O; Richard W Compans; Mark R Prausnitz; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

2.  Impact of cross-protective vaccines on epidemiological and evolutionary dynamics of influenza.

Authors:  Nimalan Arinaminpathy; Oliver Ratmann; Katia Koelle; Suzanne L Epstein; Graeme E Price; Cecile Viboud; Mark A Miller; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-07       Impact factor: 11.205

Review 3.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

4.  In vivo electroporation and non-protein based screening assays to identify antibodies against native protein conformations.

Authors:  Pirouz Daftarian; Raquibul Chowdhury; Philip Ames; Changli Wei; Alan D King; Juan Pablo de Rivero Vaccari; Lloye Dillon; Justin Price; Howard Leung; Brittany Ashlock; Enrique Mesri; Victor Perez; Stephan Züchner; Jochen Reiser; Vance Lemmon; Robert W Keane
Journal:  Hybridoma (Larchmt)       Date:  2011-10

5.  Prospects improve for long-lasting flu vaccine.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

Review 6.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost.

Authors:  Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham
Journal:  Contemp Clin Trials       Date:  2015-08-12       Impact factor: 2.226

Review 8.  Designing tomorrow's vaccines.

Authors:  Gary J Nabel
Journal:  N Engl J Med       Date:  2013-02-07       Impact factor: 91.245

9.  High-throughput sequencing of natively paired antibody chains provides evidence for original antigenic sin shaping the antibody response to influenza vaccination.

Authors:  Yann-Chong Tan; Lisa K Blum; Sarah Kongpachith; Chia-Hsin Ju; Xiaoyong Cai; Tamsin M Lindstrom; Jeremy Sokolove; William H Robinson
Journal:  Clin Immunol       Date:  2014-01-09       Impact factor: 3.969

Review 10.  Broadly neutralizing antibodies against influenza viruses.

Authors:  Nick S Laursen; Ian A Wilson
Journal:  Antiviral Res       Date:  2013-04-09       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.